Pacific Edge’s American dream

Pacific Edge’s American dream
The US Affordable Care Act can be tricky to navigate. (Image: Getty)
Paul McBeth
Pacific Edge has long wanted to crack the United States market, which it has seen for a long time as validating the hundreds of millions spent in developing its Cxbladder non-invasive cancer detection tool. More than 20 years since listing, after it was spun out of University of Otago research, the company has raised $297.23 million selling shares and convertible preference shares and as people exercised options to fund accumulated losses of $216.8m and counting. That’s not going to change any time soon after the company crashed...

More Markets

NZ sharemarket up 0.1% on flat trading day
Markets Market close

NZ sharemarket up 0.1% on flat trading day

The S&P/NZX 50 Index closed at 11,790.92, up 14.18 points or 0.12%.

Advent International eyes NZ deals with Aussie outpost
Markets

Advent International eyes NZ deals with Aussie outpost

US private equity giant says NZ key market for growth.

These shares are 'priced for awful'
Markets

These shares are 'priced for awful'

Kathmandu, SkyCity and Fletcher shares are under pressure. Some are taking the plunge.